{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:40:09Z","timestamp":1790941209320,"version":"4.1.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1097\/cco.0b013e32835280c6","type":"journal-article","created":{"date-parts":[[2012,4,3]],"date-time":"2012-04-03T10:12:07Z","timestamp":1333447927000},"page":"316-324","source":"Crossref","is-referenced-by-count":51,"title":["Targeting the DNA damage response in oncology"],"prefix":"10.1097","volume":"24","author":[{"given":"Bristi","family":"Basu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Rhoda","family":"Molife","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann S.","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-19-20210128","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease.","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"key":"R2-19-20210128","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/35077232","article-title":"Genome maintenance mechanisms for preventing cancer.","volume":"411","author":"Hoeijmakers","year":"2001","journal-title":"Nature"},{"key":"R3-19-20210128","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc2342","article-title":"DNA repair pathways as targets for cancer therapy.","volume":"8","author":"Helleday","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"R4-19-20210128","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","article-title":"The DNA damage response: making it safe to play with knives.","volume":"40","author":"Ciccia","year":"2010","journal-title":"Mol Cell"},{"key":"R5-19-20210128","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMra0804615","article-title":"DNA damage, aging, and cancer.","volume":"361","author":"Hoeijmakers","year":"2009","journal-title":"N Engl J Med"},{"key":"R6-19-20210128","doi-asserted-by":"crossref","first-page":"6973","DOI":"10.1158\/1078-0432.CCR-11-0761","article-title":"DNA repair: from genome maintenance to biomarker and therapeutic target.","volume":"17","author":"Jalal","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R7-19-20210128","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","article-title":"A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.","volume":"26","author":"Ashworth","year":"2008","journal-title":"J Clin Oncol"},{"key":"R8-19-20210128","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"R9-19-20210128","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"R10-19-20210128","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"R11-19-20210128","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.","volume":"28","author":"Fong","year":"2010","journal-title":"J Clin Oncol"},{"key":"R12-19-20210128","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"key":"R13-19-20210128","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"key":"R14-19-20210128","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1158\/1078-0432.CCR-10-0984","article-title":"Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target.","volume":"16","author":"Plummer","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R15-19-20210128","doi-asserted-by":"crossref","first-page":"7861","DOI":"10.1158\/1078-0432.CCR-05-0060","article-title":"Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma.","volume":"11","author":"Gajewski","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R16-19-20210128","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1200\/JCO.2002.09.084","article-title":"Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.","volume":"20","author":"Quinn","year":"2002","journal-title":"J Clin Oncol"},{"key":"R17-19-20210128","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2174\/138161207780414241","article-title":"Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications.","volume":"13","author":"de la Lastra","year":"2007","journal-title":"Curr Pharm Des"},{"issue":"18S","key":"R18-19-20210128","doi-asserted-by":"crossref","first-page":"8013","DOI":"10.1200\/jco.2006.24.18_suppl.8013","article-title":"First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM).","volume":"24","author":"Plummer","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"R19-19-20210128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa1011418","article-title":"Iniparib plus chemotherapy in metastatic triple-negative breast cancer.","volume":"364","author":"OShaughnessy","year":"2011","journal-title":"N Engl J Med"},{"key":"R21-19-20210128","doi-asserted-by":"crossref","first-page":"7917","DOI":"10.1158\/1078-0432.CCR-08-1223","article-title":"Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.","volume":"14","author":"Plummer","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R22-19-20210128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3322\/caac.20095","article-title":"Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.","volume":"61","author":"Yap","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"R23-19-20210128","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1158\/1078-0432.CCR-10-0523","article-title":"Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers.","volume":"16","author":"Redon","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R24-19-20210128","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, nonrandomised study.","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol"},{"issue":"6-7","key":"R25-19-20210128","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/emmm.200900041","article-title":"Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.","volume":"1","author":"Mendes-Pereira","year":"2009","journal-title":"EMBO Mol Med"},{"key":"R26-19-20210128","doi-asserted-by":"crossref","first-page":"53ra75","DOI":"10.1126\/scitranslmed.3001538","article-title":"PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.","volume":"2","author":"Dedes","year":"2010","journal-title":"Sci Transl Med"},{"key":"R28-19-20210128","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/nrclinonc.2010.172","article-title":"Synthetic lethal approaches to breast cancer therapy.","volume":"7","author":"Rehman","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"issue":"15s","key":"R29-19-20210128","first-page":"abstr","article-title":"Targeting fanconi anemia (FA) repair pathway deficiency for treatment with PARP inhibitors.","volume":"28","author":"Zhao","year":"2010","journal-title":"J Clin Oncol"},{"key":"R31-19-20210128","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1158\/1535-7163.MCT-09-0872","article-title":"ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.","volume":"9","author":"Williamson","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"R32-19-20210128","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.3324\/haematol.13201","article-title":"Chromosomal instability syndromes are sensitive to poly ADP-ribose polymerase inhibitors.","volume":"93","author":"Gaymes","year":"2008","journal-title":"Haematologica"},{"key":"R33-19-20210128","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nrd2355","article-title":"Utilizing RNA interference to enhance cancer drug discovery.","volume":"6","author":"Iorns","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"R34-19-20210128","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1158\/0008-5472.CAN-10-2836","article-title":"Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers.","volume":"71","author":"Martin","year":"2011","journal-title":"Cancer Res"},{"key":"R35-19-20210128","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ccr.2009.12.046","article-title":"DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1.","volume":"17","author":"Martin","year":"2010","journal-title":"Cancer Cell"},{"key":"R36-19-20210128","first-page":"1183","article-title":"DNA repair inhibitors: Where do we go from here DNA R","volume":"10","author":"Kelley","year":"2011","journal-title":"epair"},{"key":"R37-19-20210128","doi-asserted-by":"crossref","first-page":"6159","DOI":"10.1158\/1078-0432.CCR-10-1027","article-title":"A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer.","volume":"16","author":"Graeser","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R38-19-20210128","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1093\/jnci\/88.14.956","article-title":"UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.","volume":"88","author":"Wang","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"R39-19-20210128","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.molonc.2011.07.002","article-title":"Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs.","volume":"5","author":"Toledo","year":"2011","journal-title":"Mol Oncol"},{"key":"R40-19-20210128","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nsmb.2076","article-title":"A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations.","volume":"18","author":"Toledo","year":"2011","journal-title":"Nature Structural Molecular Biology"},{"key":"R41-19-20210128","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/bjc.2011.243","article-title":"Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.","volume":"105","author":"Peasland","year":"2011","journal-title":"Br J Cancer"},{"key":"R42-19-20210128","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1021\/jm061121y","article-title":"Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase.","volume":"50","author":"Hollick","year":"2007","journal-title":"J Med Chem"},{"key":"R43-19-20210128","doi-asserted-by":"crossref","first-page":"9152","DOI":"10.1158\/0008-5472.CAN-04-2727","article-title":"Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM.","volume":"64","author":"Hickson","year":"2004","journal-title":"Cancer Res"},{"key":"R44-19-20210128","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1158\/0008-5472.CAN-08-0763","article-title":"Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation.","volume":"68","author":"Rainey","year":"2008","journal-title":"Cancer Res"},{"key":"R45-19-20210128","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1021\/cb100428c","article-title":"Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening.","volume":"6","author":"Huang","year":"2011","journal-title":"ACS Chem Biol"},{"key":"R46-19-20210128","doi-asserted-by":"crossref","first-page":"5354","DOI":"10.1158\/0008-5472.CAN-05-4275","article-title":"Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.","volume":"66","author":"Zhao","year":"2006","journal-title":"Cancer Res"},{"key":"R47-19-20210128","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ctrv.2005.09.006","article-title":"The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer.","volume":"31","author":"Madhusudan","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"R48-19-20210128","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0960-9822(01)00048-3","article-title":"Synthetic lethality between mutation in ATM and DNA-PK(cs) during murine embryogenesis.","volume":"11","author":"Gurley","year":"2001","journal-title":"Curr Biol"},{"key":"R49-19-20210128","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1158\/1078-0432.CCR-08-2108","article-title":"Small-molecule drugs mimicking DNA damage: a new strategy for sensitizing tumors to radiotherapy.","volume":"15","author":"Quanz","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R50-19-20210128","doi-asserted-by":"crossref","first-page":"e6298","DOI":"10.1371\/journal.pone.0006298","article-title":"Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response.","volume":"4","author":"Quanz","year":"2009","journal-title":"PLoS One"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CCO.0b013e32835280c6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:37:36Z","timestamp":1786048656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001622-201205000-00019"}},"subtitle":["past, present and future perspectives"],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e32835280c6","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}